BeyondSpring is trading at $0.83, 16.74% down in pre-market, possibly reflecting profit-taking or speculative volatility; the catalyst remains unconfirmed.
- It closed at $1.00 on August 13, 2026, after a 34.27% regular-session rally.
- Searches found no confirmed August 14 announcement, earnings release, or filing directly explaining the decline.
- Coverage highlights a positive FDA orphan-drug designation for subsidiary SEED Therapeutics on August 13; broader markets are mixed, so macro sentiment does not clearly explain the move.